NV4 Stock Overview
A clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Cellectar Biosciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.40 |
52 Week High | US$3.88 |
52 Week Low | US$1.42 |
Beta | 1 |
11 Month Change | -15.49% |
3 Month Change | -32.58% |
1 Year Change | 37.93% |
33 Year Change | -75.63% |
5 Year Change | -87.12% |
Change since IPO | -99.15% |
Recent News & Updates
Recent updates
Shareholder Returns
NV4 | DE Biotechs | DE Market | |
---|---|---|---|
7D | -4.8% | 4.4% | 0.9% |
1Y | 37.9% | -16.6% | 3.0% |
Return vs Industry: NV4 exceeded the German Biotechs industry which returned -16.6% over the past year.
Return vs Market: NV4 exceeded the German Market which returned 3% over the past year.
Price Volatility
NV4 volatility | |
---|---|
NV4 Average Weekly Movement | 8.2% |
Biotechs Industry Average Movement | 6.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.4% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: NV4's share price has been volatile over the past 3 months.
Volatility Over Time: NV4's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 20 | Jim Caruso | www.cellectar.com |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors.
Cellectar Biosciences, Inc. Fundamentals Summary
NV4 fundamental statistics | |
---|---|
Market cap | €96.81m |
Earnings (TTM) | -€47.64m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.6x
P/E RatioIs NV4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NV4 income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$50.98m |
Earnings | -US$50.98m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.42 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did NV4 perform over the long term?
See historical performance and comparison